Cancer and the prothrombotic state

Lancet Oncology

Volumn 3, Issue 1, 2002, Pages 27-34

  Lip, Gregory YH ^a   Chin, Bernard SP ^a   Blann, Andrew D ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CANCER PROCOAGULANT; CISPLATIN; ETOPOSIDE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MEDROXYPROGESTERONE ACETATE; TAMOXIFEN; THROMBOPLASTIN; WARFARIN;

ANGIOGENESIS; BLOOD CLOTTING TEST; BREAST CANCER; CELL SURFACE; CLINICAL FEATURE; COMPRESSION THERAPY; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DISEASE PREDISPOSITION; ENDOTHELIUM LESION; HUMAN; HYPERCOAGULABILITY; LUNG CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; RISK FACTOR; SYMPTOMATOLOGY; THROMBOCYTE; THROMBOEMBOLISM; THROMBOGENESIS; THROMBOSIS; UTERUS CANCER; VEIN THROMBOSIS;

EID: 0036161055     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(01)00619-2     Document Type: Review

References (68)

1. The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer
2. Venous thromboembolism in malignancy and malignancy in venous thromboembolism
3. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data
4. Warfarin is safe as secondary prophylaxis in patients with cancer and a previous episode of venous thrombosis
5. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: Clinical, pathophysiologic, and therapeutic features
6. Nonbacterial thrombotic endocarditis: Clinicopathologic correlations
7. Disseminated intravascular coagulation due to malignancy
8. Cancer-associated hemolytic-uremic syndrome: Analysis of 85 cases from a national registry
9. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer
10. The incidence of occult cancer in patients with deep venous thrombosis: A prospective study
11. Occult cancer in patients with venous thromboembolism: Which patients, which cancers
12. HUS and TTP: Variable expression of a single entity
13. Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy
14. Virchow's triad revisited: The importance of soluble coagulation factors, the endothelium, and platelets
15. The significance of measuring monocyte tissue factor activity in patients with breast and colorectal cancer
16. Tumor necrosis factor induces tissue factor-like activity in human leukemia cell line U937 and peripheral blood monocytes
17. Tissue factor expression correlates with histological grade in human pancreatic cancer
18. Tissue factor expression and metastatic potential of colorectal cancer
19. Tissue factor expression in human leukocytes and tumor cells
20. In situ detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease
21. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor
22. Cancer procoagulant: A factor X activator, tumor marker and growth factor from malignant tissue
23. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia
24. Cancer procoagulant in human tumour cells: Evidence from melanoma patients
25. Hypercoagulable state in patients with advanced gastrointestinal cancer: Evidence for an acquired resistance to activated protein C
26. Hemostatic abnormalities in untreated cancer: Incidence and correlation with thrombotic and hemorrhagic complications
27. Activated protein-C resistance in cancer patients
28. The hypercoagulable state in cancer patients: Evidence for impaired thrombin inhibitions
29. Coagulopathy in the prostate cancer patient: Prevalence and clinical relevance
30. Plasma levels of D-dimer: A cross-linked fibrin-degradation product in female breast cancer
31. Prognostic significance of plasma D-dimer levels in patients with lung cancer
32. Characterization of the platelet-aggregating activity of tumor cells
33. Correlation between spontaneous metastatic potential, platelet-aggregating activity of cell extracts, and cell surface sialylation in 10 metastatic-variant derivates of a rat renal sarcoma line
34. Alterations in platelet surface sialyltransferase activity and platelet aggregation in a group of cancer patients with a high incidence of thrombosis
35. Evaluation of beta thromboglobulin levels in cancer patients: Effects of antitumour chemotherapy
36. Beta thromboglobulin and platelet-factor 4 in patients with cancer
37. Diagnostic value of fibrinopeptide A and beta thromboglobulin in acute deep vein thrombosis and pulmonary embolism
38. Increased soluble P-selectin in patients with haematological and breast cancer: A comparison with fibrinogen, plasminogen activator inhibitor and von Willebrand factor
39. The endothelium in atherothrombotic disease: Assessment of function, mechanisms and clinical implications
40. Increased plasma thrombomodulin in cancer patients
41. Cytokine mediated activation of vascular endothelium
42. Thrombosis and cancer
43. Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: Correlation between tissue factor and angiogenesis
44. Tissue factor expression and angiogenesis in human prostate carcinoma
45. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice
46. VEGF induces hyperpermeability by a direct action on endothelial cells
47. Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets
48. Interstitial fluid pressure and capillary diameter distribution in melanoma xenografts
49. Vascular architecture and microenvironmental parameters in human squamous cell carcinoma xenografts: Effects of carbogen and nicotinamide
50. Characterisation of heterogeneous distribution of tumor blood flow in the rat
51. Observation of microvascular casts of human hepatocellular carcinoma by scanning electron microscopy
52. Altered viscosity and yield stress in patients with abdominal malignancy: Relationship to deep vein thrombosis
53. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer
54. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five drug chemotherapeutic regimen. A study of 159 patients
55. Tamoxifen increases von Willebrand factor in women who underwent breast cancer surgery
56. Venous thromboembolism in malignancy and malignancy in venous thromboembolism
57. Pretreatment plasma levels of fibrinopeptide-A (FPA), D-dimer (DD) and von Willebrand factor (vWF) in patients with operable cervical cancer; influence of surgical-pathological stage, tumor size, histologic type and lymph node status
58. Activation of coagulation and fibrinolysis in patients with lung cancer: Relation to tumour stage and prognosis
59. D-dimer and CA125 levels in patients with ovarian cancer during antineoplastic therapy. Prognostic significance for the success of anticancer treatment
60. Plasma thrombosis-inducing activity in 120 patients with primary lung cancer
61. Haemostatic abnormalities and outcome in patients with operable breast cancer
62. Haematological stress syndrome in atherosclerosis
63. Screening for cancer in venous thromboembolic disease
64. Prevention of venous thromboembolism
65. Double-blind randomised trial of a very-low dose warfarin for prevention of thromboembolism in stage IV breast cancer
66. The diagnosis and treatment of thrombosis in the cancer patient
67. Guidelines for clotting studies in cancer patients
68. Surrogate markers of tumoral angiogenesis